Galera Therapeutics Inc (GRTX) Noticias

Form 3 - Initial statement of beneficial ownership of securities

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 8-K - Current report

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass...

Form 8-K - Current report

Form 8-K - Current report

Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage...

Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

MALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with...

Form 8-K - Current report

Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as...

Form 4 - Statement of changes in beneficial ownership of securities